Plain-English translation of NCT05582122 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether measuring HPV16 circulating DNA (a fragment of the virus that causes certain throat cancers) in your blood can help doctors personalize your follow-up care after cancer treatment. Instead of a one-size-fits-all schedule of clinic visits, this study explores whether patients with undetectable HPV DNA in their blood need fewer visits, while those with detectable virus get closer monitoring. If successful, this approach could reduce unnecessary appointments for most patients while catching any cancer return early.
Patients with HPV-positive throat cancer have much better outcomes than those without HPV, but current follow-up schedules don't account for this difference. This new blood test could help doctors identify which patients are at lowest risk and need fewer visits, while focusing extra attention on those at higher risk—making care more efficient and personalized.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups. The standard group will have 16 follow-up visits over 5 years, with physical exams every 2–6 months depending on the year. The new group will have only 9 visits over 5 years, with blood tests for HPV16 DNA at each visit; if your blood test is positive, you'll have additional imaging tests (MRI or PET-CT) to check for cancer return. Both groups will have annual chest CT scans if you smoke or recently quit smoking. The study runs for 5 years after your cancer treatment ends.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
France